Copyright 2023 Ephyra Networks Inc ©, All Rights Reserved

There is little doubt in the mind of many analysts that as the excitement surrounding the Information Technology age winds down, the next two decades (at least) will become the biotechnology age.  Prior to 1971, the term, biotechnology, was used extensively within the food processing and agriculture industries.  Over the last ten years, developments in biotechnology have been significant including :

• The publishing of the complete sequence of human genome in 2001
• Currently there are approximately 1,500 biotechnology companies in the USA, about 350 of which are public.
• A decade ago there were less than a dozen Cancer drugs in clinical trials, most of which were highly toxic. Today there are over 500 targeted biotech medicines, including cancer drugs (with minimal side effects), being tested.
• A wide range of patent-protected food crops which are resistant to commercial herbicides.
• A wide range of plants capable of producing proteins that act as pesticides but from within the plant.

There are many promising small to mid-capitalized biotechnology companies with exciting science/drugs and solid management teams. However, for the purpose of cross border deals between the USA/ Europe and China, many obstacles are hindering the execution of these joint venture or licensing deals.  Many of these obstacles can be resolved. Ephyra Networks has the scientific and biomedical capability to analyze and discover the most promising biotech investments.  

Our goal is to offer guidance to investors and financial institutions seeking to understand this field.  We also search for small biotech companies that may be tomorrow's industry leaders and want to find solutions for problems that are faced by the population living in China, Middle East and Africa.  

Medical Devices

Genomics

Proteomics

Gene Therapy

Bioinformatics

Telecom  Infrastructure

Biotechnology

Security & Data Mining

Oil & Gas